Max Robotics — Global Service Robot Directory + US Certification

About

Haibo Xi is a surgeon-scientist advancing the frontiers of minimally invasive urologic oncology, with a primary focus on robotic-assisted surgery for adrenal and prostate cancers. His work critically evaluates the comparative effectiveness of robotic versus traditional retroperitoneal laparoscopic approaches. In a landmark 2023 study, Xi demonstrated the specific advantages and disadvantages of robotic-assisted laparoscopic adrenalectomy (RARLA) over retroperitoneal laparoscopic adrenalectomy (RLA), providing essential guidance for surgical decision-making in adrenal tumor management. This work has already garnered 13 citations, reflecting its immediate impact on clinical practice. Xi has also made significant contributions to prostate cancer treatment, investigating the role of combined robot-assisted radical prostatectomy with androgen deprivation therapy for oligometastatic disease. By using PSA percentage decline rate as a novel assessment metric, his research offers a more nuanced understanding of tumor control in this challenging patient population. Through these studies, Xi is helping to refine surgical protocols and expand the evidence base for robotic techniques in complex oncologic cases, ultimately improving patient outcomes in urologic surgery.